dalteparin has been researched along with Rhabdomyolysis in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Rhabdomyolysis: Necrosis or disintegration of skeletal muscle often followed by myoglobinuria.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Valente-Acosta, B | 1 |
| Moreno-Sanchez, F | 1 |
| Fueyo-Rodriguez, O | 1 |
| Palomar-Lever, A | 1 |
1 other study available for dalteparin and Rhabdomyolysis
| Article | Year |
|---|---|
Rhabdomyolysis as an initial presentation in a patient diagnosed with COVID-19.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Azithromycin; Betaco | 2020 |